bluebird bio (NASDAQ:BLUE) Now Covered by StockNews.com

StockNews.com started coverage on shares of bluebird bio (NASDAQ:BLUE) in a research note published on Tuesday. The brokerage issued a sell rating on the biotechnology company’s stock.

A number of other analysts also recently commented on the stock. Barclays boosted their price objective on shares of bluebird bio from $2.00 to $40.00 and gave the stock an “overweight” rating in a report on Tuesday, December 31st. Wells Fargo & Company cut their target price on shares of bluebird bio from $40.00 to $5.00 and set an “equal weight” rating for the company in a research report on Monday, February 24th. JPMorgan Chase & Co. upgraded shares of bluebird bio from an “underweight” rating to a “neutral” rating in a research report on Monday, February 24th. Royal Bank of Canada restated a “sector perform” rating and set a $80.00 target price on shares of bluebird bio in a research report on Friday, November 15th. Finally, Baird R W cut shares of bluebird bio from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 21st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $48.10.

bluebird bio Stock Up 2.8 %

BLUE stock opened at $4.11 on Tuesday. The company has a market cap of $39.96 million, a P/E ratio of -0.11 and a beta of 0.76. bluebird bio has a 52 week low of $3.56 and a 52 week high of $33.20. The company’s 50-day moving average price is $7.02 and its 200 day moving average price is $8.72. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37.

Hedge Funds Weigh In On bluebird bio

Institutional investors have recently modified their holdings of the company. Regeneron Pharmaceuticals Inc. acquired a new position in shares of bluebird bio in the fourth quarter valued at approximately $175,000. Barclays PLC raised its position in shares of bluebird bio by 273.7% in the third quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after buying an additional 184,605 shares during the last quarter. Geode Capital Management LLC raised its position in shares of bluebird bio by 3.7% in the third quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock valued at $2,433,000 after buying an additional 166,771 shares during the last quarter. State Street Corp raised its position in shares of bluebird bio by 1.1% in the third quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock valued at $1,996,000 after buying an additional 43,382 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its position in shares of bluebird bio by 2,270.2% in the third quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 355,562 shares during the last quarter. Institutional investors and hedge funds own 87.43% of the company’s stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.